Physician profile
Peter Braud
NPI 1831548445
$747.03
in general payments reported to CMS, 2019-2025
13 companies · $204 in 2025
The $204 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.79 · 2020: $45.48 · 2021: $206 · 2022: $267 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $204.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $361.74 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $91.23 | 2021-2022 | |
| Glaxosmithkline, LLC. | $61.90 | 2022-2025 | Arexvy, Shingrix |
| Vifor Pharma, INC. | $50.47 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $45.46 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $30.64 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $18.53 | 2025 | |
| Novo Nordisk INC | $16.59 | 2025 | Rybelsus, Ozempic |
| Lundbeck LLC | $16.36 | 2025 | Rexulti |
| Lilly USA, LLC | $15.75 | 2025 | Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $13.70 | 2025 | Trintellix |
| Abbvie INC. | $13.52 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Braud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.